A phase II Trial of Weekly Paclitaxel, 5-Fluorouracil, and Leucovorin as First-Line Treatment for Metastatic Breast Cancer

被引：0
|
作者：
David M. Loesch
Lina Asmar
Vikki A. Canfield
Gregory A. Parker
Harry E. Hynes
Peter G. Ellis
William A. Ferri
Nicholas J. Robert
机构：
[1] Oncology and Hematology Associates,
[2] Inc.,undefined
[3] US Oncology,undefined
[4] Cancer Care Associates,undefined
[5] Cancer Care Associates,undefined
[6] Cancer Center of Kansas,undefined
[7] PA,undefined
[8] Oncology Hematology Associates,undefined
[9] Oncology Hematology Associates,undefined
[10] Fairfax-Prince William Hematology-Oncology PC,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 77卷
关键词：
fluorouracil; leucovorin; metastatic breast cancer; paclitaxel; therapy; weekly;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer.
引用
收藏
页码：115 / 123
页数：8
相关论文
共 50 条
  • [31] A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer
    Pan, CX
    Loehrer, P
    Seitz, D
    Helft, P
    Juliar, B
    Ansari, R
    Pletcher, W
    Vinson, J
    Cheng, L
    Sweeney, C
    ONCOLOGY, 2005, 69 (01) : 63 - 70
  • [32] A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer
    Gelmon, KA
    Tolcher, A
    O'Reilly, S
    Campbell, C
    Bryce, C
    Shenkier, T
    Ragaz, J
    Ayers, D
    Nakashima, L
    Rielly, S
    Dulude, H
    ANNALS OF ONCOLOGY, 1998, 9 (11) : 1247 - 1249
  • [33] Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    McWilliams, Robert R.
    Goetz, Matthew P.
    Morlan, Bruce W.
    Salim, Muhammad
    Rowland, Kendrith M.
    Krook, James E.
    Ames, Matthew M.
    Erlichman, Charles
    CLINICAL COLORECTAL CANCER, 2007, 6 (07) : 516 - 521
  • [34] A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial
    Tabernero, Josep
    Yoshino, Takayuki
    Stintzing, Sebastian
    de Gramont, Aimery
    Gibbs, Peter
    Jonker, Derek J.
    Nygren, Peter
    Papadimitriou, Christos
    Prager, Gerald W.
    Tell, Roger
    Lenz, Heinz-Josef
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (01): : 28 - 37
  • [35] Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer
    Han, S.
    Park, S.
    Lee, K.
    Song, H.
    Lee, N.
    Lee, K.
    Choi, I
    Lee, M.
    Kim, M.
    Oh, D.
    Im, S.
    Kim, W.
    Bang, Y.
    Kim, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 46 - 46
  • [36] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Juan José Reina
    Jorge Aparicio
    Javier Salvador
    José María Puerto Pica
    Antonio Rueda
    Antonio Lorenzo
    Carlos González de la Puente
    Pablo Borrega
    José Andrés Moreno-Nogueira
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 339 - 345
  • [37] First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule
    Masi, G
    Allegrini, G
    Cupini, S
    Marcucci, L
    Cerri, E
    Brunetti, I
    Fontana, E
    Ricci, S
    Andreuccetti, M
    Falcone, A
    ANNALS OF ONCOLOGY, 2004, 15 (12) : 1766 - 1772
  • [38] Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer
    Han, S.
    Park, S. R.
    Lee, K.
    Song, H.
    Kim, M. A.
    Oh, D.
    Im, S.
    Kim, W.
    Bang, Y.
    Kim, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
  • [40] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
12345